[1]
Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Jan 15:64(2):e1-e33. doi: 10.1093/cid/ciw694. Epub 2016 Dec 8
[PubMed PMID: 27932390]
Level 1 (high-level) evidence
[2]
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. American journal of respiratory and critical care medicine. 2006 Oct 15:174(8):935-52
[PubMed PMID: 17021358]
[3]
Hassan HM, Guo HL, Yousef BA, Luyong Z, Zhenzhou J. Hepatotoxicity mechanisms of isoniazid: A mini-review. Journal of applied toxicology : JAT. 2015 Dec:35(12):1427-32. doi: 10.1002/jat.3175. Epub 2015 Jun 10
[PubMed PMID: 26095833]
[4]
Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Bronstein AC, Rivers LJ, Pham NPT, Weber J. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. Clinical toxicology (Philadelphia, Pa.). 2021 Dec:59(12):1282-1501. doi: 10.1080/15563650.2021.1989785. Epub
[PubMed PMID: 34890263]
[5]
Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, Lee WM, Davern TJ, Kleiner DE, Gu J, Hoofnagle JH, US Drug-Induced Liver Injury Network Investigators. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015 Sep:13(9):1676-82.e1. doi: 10.1016/j.cgh.2015.02.024. Epub 2015 Feb 24
[PubMed PMID: 25724701]
Level 3 (low-level) evidence
[6]
Wason S, Lacouture PG, Lovejoy FH Jr. Single high-dose pyridoxine treatment for isoniazid overdose. JAMA. 1981 Sep 4:246(10):1102-4
[PubMed PMID: 7265398]
[7]
Citak A, Kaya O, Uçsel R, Karaböcüoğlu M, Uzel N. Acute isoniazid neurotoxicity in childhood. The Turkish journal of pediatrics. 2002 Jan-Mar:44(1):54-7
[PubMed PMID: 11858381]
[8]
Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clinical pharmacokinetics. 1979 Nov-Dec:4(6):401-22
[PubMed PMID: 391461]
[9]
Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, Ramegowda PH, Amarapurkar AD, Joshi K, Wangikar PP. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. Journal of gastroenterology and hepatology. 2013 Aug:28(8):1368-74. doi: 10.1111/jgh.12194. Epub
[PubMed PMID: 23875638]
[10]
Constantinescu SM, Buysschaert B, Haufroid V, Broly F, Jadoul M, Morelle J. Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy - case report and literature review. BMC nephrology. 2017 Sep 4:18(1):282. doi: 10.1186/s12882-017-0703-6. Epub 2017 Sep 4
[PubMed PMID: 28870161]
Level 3 (low-level) evidence
[11]
Jaramillo-Valverde L, Levano KS, Tarazona DD, Capristano S, Zegarra-Chapoñan R, Sanchez C, Yufra-Picardo VM, Tarazona-Santos E, Ugarte-Gil C, Guio H. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients. Molecular genetics & genomic medicine. 2022 Aug:10(8):e1987. doi: 10.1002/mgg3.1987. Epub 2022 Jun 24
[PubMed PMID: 35751408]
[12]
Lee Loy J, Chamarthi G, Koratala A. An uncommon cause of loss of vision in a dialysis patient with lupus. Clinical case reports. 2019 Jan:7(1):244-245. doi: 10.1002/ccr3.1954. Epub 2018 Dec 12
[PubMed PMID: 30656056]
Level 3 (low-level) evidence
[13]
Si M, Li H, Chen Y, Peng H. Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. BMJ case reports. 2018 May 18:2018():. pii: bcr-2017-223187. doi: 10.1136/bcr-2017-223187. Epub 2018 May 18
[PubMed PMID: 29776936]
Level 3 (low-level) evidence
[14]
Noguera-Pons R, Borrás-Blasco J, Romero-Crespo I, Antón-Torres R, Navarro-Ruiz A, González-Ferrandez JA. Optic neuritis with concurrent etanercept and isoniazid therapy. The Annals of pharmacotherapy. 2005 Dec:39(12):2131-5
[PubMed PMID: 16264061]
[15]
Gourishankar A, Navarro F, Debroy AN, Smith KC. Isoniazid hepatotoxicity with clinical and histopathology correlate. Annals of clinical and laboratory science. 2014 Winter:44(1):87-90
[PubMed PMID: 24695480]
[16]
Philipose J, Suchman KI, Aronsky D, Lee TP. A Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis. Cureus. 2022 Feb:14(2):e22452. doi: 10.7759/cureus.22452. Epub 2022 Feb 21
[PubMed PMID: 35345710]
Level 3 (low-level) evidence
[17]
Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 1999 Aug:3(8):703-10
[PubMed PMID: 10460103]
[18]
Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014 Jun:74(8):839-54. doi: 10.1007/s40265-014-0222-8. Epub
[PubMed PMID: 24846578]
[19]
Babalik A, Babalik A, Mannix S, Francis D, Menzies D. Therapeutic drug monitoring in the treatment of active tuberculosis. Canadian respiratory journal. 2011 Jul-Aug:18(4):225-9
[PubMed PMID: 22059181]
[20]
Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. European journal of emergency medicine : official journal of the European Society for Emergency Medicine. 2005 Apr:12(2):78-85
[PubMed PMID: 15756083]
[21]
Siskind MS, Thienemann D, Kirlin L. Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature. Nephron. 1993:64(2):303-6
[PubMed PMID: 8321366]
Level 3 (low-level) evidence
[22]
Kocabay G, Erelel M, Tutkun IT, Ecder T. Optic neuritis and bitemporal hemianopsia associated with isoniazid treatment in end-stage renal failure. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2006 Dec:10(12):1418-9
[PubMed PMID: 17171829]
[23]
Uzman S, Uludağ Yanaral T, Toptaş M, Koç A, Taş A, Bican G. Acute isoniazid intoxication: an uncommon cause of convulsion, coma and acidosis. Tuberkuloz ve toraks. 2013:61(1):50-3
[PubMed PMID: 23581267]
[24]
Orlowski JP, Paganini EP, Pippenger CE. Treatment of a potentially lethal dose isoniazid ingestion. Annals of emergency medicine. 1988 Jan:17(1):73-6
[PubMed PMID: 3337420]
[25]
Centers for Disease Control and Prevention (CDC). Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. MMWR. Morbidity and mortality weekly report. 2010 Mar 5:59(8):224-9
[PubMed PMID: 20203555]
[26]
de' Clari F. The paradoxical anticonvulsive and awakening effect of high-dose pyridoxine treatment for isoniazid intoxication. Archives of internal medicine. 1992 Nov:152(11):2346-7
[PubMed PMID: 1290558]
[27]
Blanchard PD, Yao JD, McAlpine DE, Hurt RD. Isoniazid overdose in the Cambodian population of Olmsted County, Minnesota. JAMA. 1986 Dec 12:256(22):3131-3
[PubMed PMID: 3783848]
[28]
Mowry JB, Shepherd G, Hoffman RS, Lavergne V, Gosselin S, Nolin TD, Vijayan A, Kielstein JT, Roberts DM, Ghannoum M, Extracorporeal Treatments in Poisoning workgroup. Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup. Pharmacotherapy. 2021 May:41(5):463-478. doi: 10.1002/phar.2519. Epub 2021 Apr 3
[PubMed PMID: 33660266]
Level 1 (high-level) evidence
[29]
Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug safety. 1996 Dec:15(6):394-405
[PubMed PMID: 8968694]
[30]
Farrell FJ, Keeffe EB, Man KM, Imperial JC, Esquivel CO. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. Digestive diseases and sciences. 1994 Oct:39(10):2255-9
[PubMed PMID: 7924752]
[31]
Kalsi SS, Wood DM, Waring WS, Dargan PI. Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose? Open access emergency medicine : OAEM. 2011:3():69-76. doi: 10.2147/OAEM.S24962. Epub 2011 Oct 13
[PubMed PMID: 27147854]
[32]
Self TH, Chrisman CR, Baciewicz AM, Bronze MS. Isoniazid drug and food interactions. The American journal of the medical sciences. 1999 May:317(5):304-11
[PubMed PMID: 10334118]
[33]
Shimokawa Y, Yoda N, Kondo S, Yamamura Y, Takiguchi Y, Umehara K. Inhibitory Potential of Twenty Five Anti-tuberculosis Drugs on CYP Activities in Human Liver Microsomes. Biological & pharmaceutical bulletin. 2015:38(9):1425-9. doi: 10.1248/bpb.b15-00313. Epub 2015 Jun 20
[PubMed PMID: 26094899]
[34]
Lejonc JL, Schaeffer A, Brochard P, Portos JL. [Paroxystic hypertension after ingestion of gruyere cheese during isoniazide treatment: a report on two cases (author's transl)]. Annales de medecine interne. 1980:131(6):346-8
[PubMed PMID: 7469238]
Level 3 (low-level) evidence
[35]
Yang XG, Mou YH, Wang YJ, Wang J, Li YY, Kong RH, Ding M, Wang D, Guo C. Design, Synthesis, and Evaluation of Monoamine Oxidase A Inhibitors⁻Indocyanine Dyes Conjugates as Targeted Antitumor Agents. Molecules (Basel, Switzerland). 2019 Apr 10:24(7):. doi: 10.3390/molecules24071400. Epub 2019 Apr 10
[PubMed PMID: 30974737]
[36]
Miki M, Ishikawa T, Okayama H. An outbreak of histamine poisoning after ingestion of the ground saury paste in eight patients taking isoniazid in tuberculous ward. Internal medicine (Tokyo, Japan). 2005 Nov:44(11):1133-6
[PubMed PMID: 16357449]
[37]
Glatstein M, Carbell G, Scolnik D, Rimon A, Banerji S, Hoyte C. Pyridoxine for the treatment of isoniazid-induced seizures in intentional ingestions: The experience of a national poison center. The American journal of emergency medicine. 2018 Oct:36(10):1775-1778. doi: 10.1016/j.ajem.2018.01.085. Epub 2018 Jan 31
[PubMed PMID: 29397257]
[38]
Arsalan R, Sabzwari S. Isoniazid induced motor-dominant neuropathy. JPMA. The Journal of the Pakistan Medical Association. 2015 Oct:65(10):1131-3
[PubMed PMID: 26440850]
[39]
Yadav R, Kumar M, Kumar N, Chacham S. Pyridoxine in isoniazid-induced psychosis. Sudanese journal of paediatrics. 2022:22(2):190-192. doi: 10.24911/SJP.106-1584524803. Epub
[PubMed PMID: 36875946]
[40]
Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. Journal of acquired immune deficiency syndromes (1999). 2018 Apr 1:77(4):405-412. doi: 10.1097/QAI.0000000000001610. Epub
[PubMed PMID: 29239900]
[41]
Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug, healthcare and patient safety. 2014:6():145-9. doi: 10.2147/DHPS.S68837. Epub 2014 Oct 20
[PubMed PMID: 25364275]